SpringWorks Therapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of SpringWorks Therapeutics generated cash of -$222,795,000, which is less than the previous year. Cash used in financing activities reached the amount of $296,639,000 last year. Net change in cash is therefore $108,598,000.
Cash Flow
| 2017 | -2.23M | -44K | 12.55M |
|---|---|---|---|
| 2018 | -14.70M | -293K | 50.37M |
| 2019 | -47.44M | -4.26M | 333.70M |
| 2020 | -32.19M | -418.83M | 270.48M |
| 2021 | -127.87M | 83.59M | 1.15M |
| 2022 | -161.56M | -215.59M | 340.70M |
| 2023 | -222.79M | 34.75M | 296.63M |
SWTX Cash Flow Statement (2017 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
Cash at beginning of period | 68.06M | 104.52M | 147.65M | 328.19M | 46.18M | 10.27M | 0 |
Operating activities | |||||||
Net income | -325.10M | -277.41M | -173.91M | -45.57M | -58.30M | -17.81M | -4.63M |
| Adjustments to reconcile net income to cash generated by operating activities: | |||||||
Depreciation and amortization | 1.66M | 765K | 490K | 349K | 192K | 17K | 3.18K |
Stock-based compensation expense | 94.53M | 72.96M | 38.44M | 10.03M | 3.10M | 0 | 0 |
| Deferred income tax benefit | 94.53M | 72.96M | 38.44M | 10.03M | 3.10M | 0 | 0 |
| Changes in operating assets and liabilities: | |||||||
Accounts receivable, net | -5.93M | 0 | 0 | 0 | 0 | 0 | 0 |
Inventories | -3.10M | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts payable | -196K | 4.16M | 2.07M | -1.30M | 1.88M | 491K | 283K |
Cash generated by operating activities | -222.79M | -161.56M | -127.87M | -32.19M | -47.44M | -14.70M | -2.23M |
Investing activities | |||||||
Purchases Of Investments | -575.72M | -481.05M | -305.42M | -442.69M | -3.59M | 0 | 0 |
Investments In Property Plant And Equipment | -7.38M | -10.19M | -2.01M | -642K | -670K | -293K | -44K |
Acquisitions Net | -2.8M | -4.2M | 2.01M | -3.5M | -3.59M | 0 | 0 |
Cash generated by investing activities | 34.75M | -215.59M | 83.59M | -418.83M | -4.26M | -293K | -44K |
Financing activities | |||||||
Common Stock Issued | 299.3M | 340.06M | 1.15M | 269.59M | 169.73M | 0 | 12.55M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | -2.8M | -1.34M | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash used in financing activities | 296.63M | 340.70M | 1.15M | 270.48M | 333.70M | 50.37M | 12.55M |
Net Change In Cash | 108.59M | -36.45M | -43.12M | -180.53M | 282.00M | 35.37M | 10.27M |
Cash at end of period | 176.66M | 68.06M | 104.52M | 147.65M | 328.19M | 45.64M | 10.27M |
| Data source | Data source | Data source | Data source | Data source |